Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Spatial biomarkers of CAR-T treatment response in relapsed refractory multiple myeloma

Julia Wang, Chenchen Peng, Reyka Jayasinghe, Michael Slade, Xiangwei Fang, Julie Fortier, Mark Fiala, Yuxuan Pan, Preet Lal, Yuting Zhao, Kiran Vij, Chaitanya Acharya, George Mulligan, John DiPersio, Feng Chen, Ravi Vij, Li Ding

Blood (2025) 146 (Supplement 1): 5804.

https://doi.org/10.1182/blood-2025-5804

Published: 2025

Journal Articles

primary analysis of Phase ib trial of duvelisib for cytokine release syndrome prophylaxis in patients undergoing chimeric antigen receptor T cell therapy for non-hodgkins lymphoma

Michael Slade, Michael Rettig, Parmeshwar Amatya, Zachary Crees, Brad Kahl, Neha Mehta-Shah, Dilan Patel, David Russler-Germain, Nancy Bartlett, Amanda Cashen, Iskra Pusic, Geoffrey Uy, John DiPersio, Armin Ghobadi

Blood (2025) 146 (Supplement 1): 929.

https://doi.org/10.1182/blood-2025-929

Published: 2025

Journal Articles

A Phase 1 study evaluating NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel (tisa-cel), post-axicabtagene ciloleucel (axi-cel), or post-lisocabtagene maraleucel (liso-cel) in Relapsed/Refractory large B-cell lymphoma

Zachary Crees, Armin Ghobadi, Elizabeth Budde, Ahmed Galal, Chenyu Lin, Donghoon Choi, Sun-Kyoung Im, Hye Jeong, Alex Oh, Michael Rettig, John DiPersio

Blood (2025) 146 (Supplement 1): 926.

https://doi.org/10.1182/blood-2025-926

Published: 2025

Journal Articles

Integrative surfaceome mapping in AML identifies CD85d as an immunotherapy target

Omar Ibrahim, Michael Rettig, Reyka Jayasinghe, Li Ding, John DiPersio

Blood (2025) 146 (Supplement 1): 338.

https://doi.org/10.1182/blood-2025-338

Published: 2025

Journal Articles

Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy

Zachary Crees, Mark Schroeder, Michael Slade, Keith Stockerl-Goldstein, Ravi Vij, Ella Sorani, Irit Glicko-Kabir, Michael Rettig, John DiPersio

Blood (2025) 146 (Supplement 1): 5957.

https://doi.org/10.1182/blood-2025-5957

Published: 2025

Journal Articles

Motixafortide (CXCR4 inhibition) alone and in combination with natalizumab (VLA-4 inhibition) to mobilize hematopoietic stem cells for gene therapy in sickle cell disease: A first-in-human, safety and feasibility study

Zachary Crees, Michael Rettig, Peter Ruminski, Reyka Jayasinghe, Stephen Persaud, Stephanie Christ, Feng Gao, Hailey Sappington, Samantha Bauer, Sana Saif Ur Rehman, Suzanne Thibodeaux, Ella Sorani, Allison King, John DiPersio

Blood (2025) 146 (Supplement 1): 5956.

https://doi.org/10.1182/blood-2025-5956

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2025-1001

Published: 2025

Journal Articles

BACH2 regulates T cell lineage states to overcome dysfunction driven by tonic CAR signaling

Blood (2025) 146 (Supplement 1): 108.

https://doi.org/10.1182/blood-2025-108

Published: 2025

Journal Articles

Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study

Blood (2025) 146 (Supplement 1): 2532.

https://doi.org/10.1182/blood-2025-2532

Published: 2025

Journal Articles

EMU-116: An oral CXCR4 antagonist as mobilizer of stem and immune cells in normal, neutropenic and sickle cell mice.

Lawrence Wilson, Priscilla Davidson, Petra Foster, Hayden Kissick, John Petros, Eric Miller, Yesim Tahirovic, Leon Jacobs, Justin Yoo, Vivien Sheehan, Ezhilarasi Chendamarai, Michael Rettig, John DiPersio, Dennis Liotta

Blood (2025) 146 (Supplement 1): 4323.

https://doi.org/10.1182/blood-2025-4323

Published: 2025

Journal Articles

An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation

Ramzi Abboud, Feng Gao, Maggie Nash, Jeffrey King, Samantha Bauer, Camille Abboud, Zachary Crees, Meagan Jacoby, Iskra Pusic, Mark Schroeder, Samuel Urrutia, Geoffrey Uy, John DiPersio

Blood (2025) 146 (Supplement 1): 2459.

https://doi.org/10.1182/blood-2025-2459

Published: 2025

Journal Articles

A first-in-human phase 1 Study of cbx-250, a TCR-mimetic bispecific T cell engager targeting CG1/ HLA-a*02:01 in patients with relapsed or refractory AML, HR-MDS, or CMML (CROSSCHECK-001) (Trial in Progress)

Brian Ball, Stephen Strickland, Briggs Morrison, John DiPersio, Shaliny Kushwaha, Benjamin Lee, Rachel Ghiraldi, Kevin Cho, John Goll, David Sallman, Ghayas Issa

Blood (2025) 146 (Supplement 1): 3430.

https://doi.org/10.1182/blood-2025-3430

Published: 2025

Journal Articles

Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708

Ibrahim Aldoss, Carl Shultz, Bradley Hunter, David Swoboda, Pau Montesinos, Sarit Assouline, Shaun Fleming, Carolyn Grove, Andre Schuh, David Taussig, Karla Malloy, Enoch Cobbina, Jingshan Zhang, Mila Ayash-Rashkovsky, Jessica Clement, Eytan Stein, John DiPersio

Blood (2025) 146 (Supplement 1): 3425.

https://doi.org/10.1182/blood-2025-3425

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 3418.

https://doi.org/10.1182/blood-2025-3418

Published: 2025

Journal Articles

Favorable safety and efficacy in a phase II trial using duvelisib maintenance after autologous stem cell transplant in T-cell and B-cell non-Hodgkin lymphomas

Hunter Cochran, Raya Saba, Ningying Wu, Neha Mehta-Shah, Armin Ghobadi, John DiPersio, Amanda Cashen

Blood (2025) 146 (Supplement 1): 1860.

https://doi.org/10.1182/blood-2025-1860

Published: 2025

Journal Articles

Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises

Blood (2024) 144 (Supplement 1): 513.

https://doi.org/10.1182/blood-2024-204888

Published: 2024

Journal Articles

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Blood (2023) 142 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2023-192042

Published: 2023

Journal Articles

Mechanistic Studies of Cytokine Release Syndrome (CRS) with Roles of Interferon-Gamma (IFN-g) and Tumor Necrosis Factor Alpha (TNF-α) While Maintaining CAR-T Function in Vitro

Parmeshwar N Amatya, Jingyu Xiang, Julie O'Neal, Julie K. Ritchey, Alun J Carter, Matthew L. Cooper, John DiPersio

Blood (2023) 142 (Supplement 1): 2086.

https://doi.org/10.1182/blood-2023-187449

Published: 2023

Journal Articles

One Year Follow-up on the First Patient Treated with Nula-Cel: An Autologous CRISPR/Cas9 Gene Corrected CD34+ Cell Product to Treat Sickle Cell Disease

Blood (2023) 142 (Supplement 1): 5000.

https://doi.org/10.1182/blood-2023-188963

Published: 2023

Journal Articles

Targeting Normal Myelopoiesis Negatively Affects CAR T Cell Activity

Miriam Y Kim, Matthew L. Cooper, Julie K. Ritchey, Julie O'Neal, John DiPersio

Blood (2023) 142 (Supplement 1): 2077.

https://doi.org/10.1182/blood-2023-186015

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Spatial biomarkers of CAR-T treatment response in relapsed refractory multiple myeloma

primary analysis of Phase ib trial of duvelisib for cytokine release syndrome prophylaxis in patients undergoing chimeric antigen receptor T cell therapy for non-hodgkins lymphoma

A Phase 1 study evaluating NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel (tisa-cel), post-axicabtagene ciloleucel (axi-cel), or post-lisocabtagene maraleucel (liso-cel) in Relapsed/Refractory large B-cell lymphoma

Integrative surfaceome mapping in AML identifies CD85d as an immunotherapy target

Motixafortide + G-CSF hematopoietic stem cell mobilization in patients with multiple myeloma following quadruplet induction therapy

Motixafortide (CXCR4 inhibition) alone and in combination with natalizumab (VLA-4 inhibition) to mobilize hematopoietic stem cells for gene therapy in sickle cell disease: A first-in-human, safety and feasibility study

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

BACH2 regulates T cell lineage states to overcome dysfunction driven by tonic CAR signaling

Robust HbF induction and improvement of anemia and hemolysis with base editing in sickle cell disease: Safety and efficacy findings from the ongoing BEACON study

EMU-116: An oral CXCR4 antagonist as mobilizer of stem and immune cells in normal, neutropenic and sickle cell mice.

An open-label phase I study of JAK inhibitor ruxolitinib with and without CTLA-4 ig abatacept for the prophylaxis of graft-versus-host ddsease and cytokine release syndrome after T-cell replete haploidentical peripheral blood hematopoietic cell transplantation

A first-in-human phase 1 Study of cbx-250, a TCR-mimetic bispecific T cell engager targeting CG1/ HLA-a*02:01 in patients with relapsed or refractory AML, HR-MDS, or CMML (CROSSCHECK-001) (Trial in Progress)

Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Favorable safety and efficacy in a phase II trial using duvelisib maintenance after autologous stem cell transplant in T-cell and B-cell non-Hodgkin lymphomas

Initial Results from the BEACON Clinical Study: A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients with Sickle Cell Disease with Severe Vaso-Occlusive Crises

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

Mechanistic Studies of Cytokine Release Syndrome (CRS) with Roles of Interferon-Gamma (IFN-g) and Tumor Necrosis Factor Alpha (TNF-α) While Maintaining CAR-T Function in Vitro

One Year Follow-up on the First Patient Treated with Nula-Cel: An Autologous CRISPR/Cas9 Gene Corrected CD34+ Cell Product to Treat Sickle Cell Disease

Targeting Normal Myelopoiesis Negatively Affects CAR T Cell Activity

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only